Asciminib: First Approval

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Asciminib is a novel, orally administered small molecule inhibitor targeting the myristoyl pocket of BCR-ABL1.
• It is developed for hematological malignancies, specifically Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML).
• Asciminib demonstrates activity against mutations like T315I, which confer resistance to ATP-binding site TKIs.

Purpose of the Study:

• To summarize the development milestones of asciminib.
• To highlight its first approval for specific patient populations with Ph+ CML.

Main Methods:

• Review of clinical development data for asciminib.
• Analysis of regulatory submissions and approvals.

Main Results:

• Asciminib received accelerated approval in October 2021 for adults with Ph+ CML-CP previously treated with ≥ 2 TKIs.
• Full approval was granted for adults with Ph+ CML-CP harboring the T315I mutation.
• Asciminib is under regulatory review in the EU and in Phase 1-3 development for various CML patient groups.

Conclusions:

• Asciminib represents a significant advancement in CML treatment.
• Its targeted allosteric inhibition offers a new therapeutic strategy for resistant Ph+ CML.
• Ongoing development aims to expand its use across different lines of therapy and patient demographics.